1170 related articles for article (PubMed ID: 24662102)
21. Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study.
Taipale H; Tanskanen A; Koponen M; Tolppanen AM; Tiihonen J; Hartikainen S
Int Clin Psychopharmacol; 2014 Jul; 29(4):216-23. PubMed ID: 24608822
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Hansen RA; Gartlehner G; Webb AP; Morgan LC; Moore CG; Jonas DE
Clin Interv Aging; 2008; 3(2):211-25. PubMed ID: 18686744
[TBL] [Abstract][Full Text] [Related]
23. Drugs for cognitive loss and dementia.
Treat Guidel Med Lett; 2013 Oct; 11(134):95-100; quiz 1 p following p100.. PubMed ID: 24081314
[TBL] [Abstract][Full Text] [Related]
24. Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration.
Kurz A; Van Baelen B
Dement Geriatr Cogn Disord; 2004; 18(2):217-26. PubMed ID: 15237280
[TBL] [Abstract][Full Text] [Related]
25. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
[TBL] [Abstract][Full Text] [Related]
26. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.
Van Dam D; Abramowski D; Staufenbiel M; De Deyn PP
Psychopharmacology (Berl); 2005 Jun; 180(1):177-90. PubMed ID: 15654502
[TBL] [Abstract][Full Text] [Related]
27. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease.
Lampela P; Tolppanen AM; Tanskanen A; Tiihonen J; Lavikainen P; Hartikainen S; Taipale H
Ann Med; 2017 May; 49(3):230-239. PubMed ID: 27786552
[TBL] [Abstract][Full Text] [Related]
28. Effective pharmacological management of Alzheimer's disease.
Atri A
Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
[TBL] [Abstract][Full Text] [Related]
29. Anti-Alzheimer drugs: life-threatening adverse effects.
Prescrire Int; 2007 Feb; 16(87):16. PubMed ID: 17326275
[TBL] [Abstract][Full Text] [Related]
30. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
Ehret MJ; Chamberlin KW
Clin Ther; 2015 Aug; 37(8):1604-16. PubMed ID: 26122885
[TBL] [Abstract][Full Text] [Related]
31. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Prasher VP
Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
[TBL] [Abstract][Full Text] [Related]
32. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
[TBL] [Abstract][Full Text] [Related]
33. [Advances in Alzheimer's disease treatment].
Nourhashémi F
Rev Med Interne; 2006 Aug; 27(8):585-7. PubMed ID: 16782240
[No Abstract] [Full Text] [Related]
34. Drug therapy of dementia in elderly patients. A review.
Olsen CE; Poulsen HD; Lublin HK
Nord J Psychiatry; 2005; 59(2):71-7. PubMed ID: 16195103
[TBL] [Abstract][Full Text] [Related]
35. Comparative Efficacy and Acceptability of Cholinesterase Inhibitors and Memantine Based on Dosage in Patients with Vascular Cognitive Impairment: A Network Meta-analysis.
Shi X; Ren G; Cui Y; Xu Z
Curr Alzheimer Res; 2022; 19(2):133-145. PubMed ID: 35048806
[TBL] [Abstract][Full Text] [Related]
36. [Are anti-dementia drugs worthwhile?].
Lang CJ
MMW Fortschr Med; 2007 Sep; 149 Suppl 3():85-9. PubMed ID: 17955784
[TBL] [Abstract][Full Text] [Related]
37. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
[TBL] [Abstract][Full Text] [Related]
38. Understanding the latest advances in pharmacologic interventions for Alzheimer's disease.
van Dyck CH
CNS Spectr; 2004 Jul; 9(7 Suppl 5):24-8. PubMed ID: 15241297
[TBL] [Abstract][Full Text] [Related]
39. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.
Lockhart IA; Mitchell SA; Kelly S
Dement Geriatr Cogn Disord; 2009; 28(5):389-403. PubMed ID: 19893314
[TBL] [Abstract][Full Text] [Related]
40. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
